Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?

Yuh-Chen Kuo, Hann-Chorng Kuo, Yuh-Chen Kuo, Hann-Chorng Kuo

Abstract

Intravesical onabotulinumtoxinA (BoNT-A) injections have been proposed to treat both overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS) in patients with refractory conditions. We compared adverse events (AEs) after BoNT-A treatment between IC/BPS and OAB in women. IC/BPS patients who failed conventional treatments were enrolled to receive suburothelial injections of BoNT-A (100 U) followed by hydrodistention. Age matched OAB female patients refractory to antimuscarinic agents underwent BoNT-A (100 U) injections. The bladder capacity, maximum flow rate (Qmax), post-void residual (PVR), and voiding efficiency (VE) at baseline, 3 and 6 months, and the post-treatment AEs were analyzed between groups. Finally, 89 IC/BPS and 72 OAB women were included. In the OAB group, the bladder capacity and PVR increased, and VE decreased significantly at three and six months after BoNT-A treatment. In the IC/BPS group, the Qmax increased significantly at six months. There were significant differences in changes of capacity, Qmax, PVR and VE between the two groups. Moreover, OAB patients suffered more frequently from events of hematuria, UTI, and large PVR (>200 mL), but less frequently from events of straining to void. In conclusion, OAB women had higher PVR volume and lower VE than those in IC/BPS after BoNT-A injections. These results imply that the bladder contractility of OAB patients are more susceptible to BoNT-A, which might reflect the different mechanisms of action of Botox on bladder dysfunction. Further investigations to confirm this hypothesis are warranted.

Keywords: adverse events; interstitial cystitis; onabotulinumtoxinA; overactive bladder.

Figures

Figure 1
Figure 1
The changes of bladder capacity, maximum flow rate (Qmax), postvoid residual (PVR), and voiding efficiency (VE) in patients with overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS) after BoNT-A injections. Data are expressed as mean ± standard deviation. * p < 0.05, ** p < 0.01, *** p < 0.001 when compared with baseline data in each group. Paired t test was used. #p < 0.05, ##p < 0.01, ###p < 0.001 when compared between groups. Independent t test was used.
Figure 2
Figure 2
Instruction of patient selection from the databases of overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS).

References

    1. Haylen B.T., Freeman R.M., Swift S.E., Cosson M., Davila G.W., Deprest J., Dwyer P.L., Fatton B., Kocjancic E., Lee J., et al. An international urogynecological association (iuga)/international continence society (ics) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Neurourol. Urodyn. 2011;30:2–12.
    1. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., Coyne K., Kelleher C., Hampel C., Artibani W., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the epic study. Eur. Urol. 2006;50:1306–1314. doi: 10.1016/j.eururo.2006.09.019.
    1. Malmsten U.G., Molander U., Peeker R., Irwin D.E., Milsom I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: A longitudinal population-based survey in men aged 45–103 years. Eur. Urol. 2010;58:149–156. doi: 10.1016/j.eururo.2010.03.014.
    1. Wein A.J., Rackley R.R. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J. Urol. 2006;175:S5–S10. doi: 10.1016/S0022-5347(05)00313-7.
    1. Meng E., Lin W.-Y., Lee W.-C., Chuang Y.-C. Pathophysiology of overactive bladder. LUTS Low. Urin. Tract Symptoms. 2012;4:48–55. doi: 10.1111/j.1757-5672.2011.00122.x.
    1. Fowler C.J., Auerbach S., Ginsberg D., Hale D., Radziszewski P., Rechberger T., Patel V.D., Zhou J., Thompson C., Kowalski J.W. Onabotulinumtoxina improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur. Urol. 2012;62:148–157. doi: 10.1016/j.eururo.2012.03.005.
    1. Kuo H.C. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin a injection for idiopathic detrusor overactivity. Neurourol. Urodyn. 2011;30:1497–1502. doi: 10.1002/nau.21132.
    1. Mohee A., Khan A., Harris N., Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (oab) BJU Int. 2013;111:106–113. doi: 10.1111/j.1464-410X.2012.11282.x.
    1. Nitti V.W., Dmochowski R., Herschorn S., Sand P., Thompson C., Nardo C., Yan X., Haag-Molkenteller C. Onabotulinumtoxina for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J. Urol. 2013;189:2186–2193. doi: 10.1016/j.juro.2012.12.022.
    1. Kuo H.C., Liao C.H., Chung S.D. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome. Eur. Urol. 2010;58:919–926. doi: 10.1016/j.eururo.2010.09.007.
    1. Propert K.J., Schaeffer A.J., Brensinger C.M., Kusek J.W., Nyberg L.M., Landis J.R. A prospective study of interstitial cystitis: Results of longitudinal followup of the interstitial cystitis data base cohort. The interstitial cystitis data base study group. J. Urol. 2000;163:1434–1439. doi: 10.1016/S0022-5347(05)67637-9.
    1. Butrick C.W. Interstitial cystitis and chronic pelvic pain: New insights in neuropathology, diagnosis, and treatment. Clin. Obstet. Gynecol. 2003;46:811–823. doi: 10.1097/00003081-200312000-00011.
    1. Hanno P.M., Erickson D., Moldwin R., Faraday M.M. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: Aua guideline amendment. J. Urol. 2015;193:1545–1553. doi: 10.1016/j.juro.2015.01.086.
    1. Giannantoni A., Mearini E., Del Zingaro M., Proietti S., Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr. Drug Deliv. 2010;7:1–4. doi: 10.2174/156720110790396463.
    1. Kuo H.C. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain physician. 2013;16:E15–E23.
    1. Kuo H.C., Chancellor M.B. Comparison of intravesical botulinum toxin type a injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104:657–661.
    1. Pinto R., Lopes T., Silva J., Silva C., Dinis P., Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J. Urol. 2013;189:548–553. doi: 10.1016/j.juro.2012.09.027.
    1. Gormley E.A., Lightner D.J., Burgio K.L., Chai T.C., Clemens J.Q., Culkin D.J., Das A.K., Foster H.E., Jr., Scarpero H.M., Tessier C.D., et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: Aua/sufu guideline. J. Urol. 2012;188:2455–2463. doi: 10.1016/j.juro.2012.09.079.
    1. Coyne K.S., Matza L.S., Kopp Z., Abrams P. The validation of the patient perception of bladder condition (ppbc): A single-item global measure for patients with overactive bladder. Eur. Urol. 2006;49:1079–1086. doi: 10.1016/j.eururo.2006.01.007.
    1. Propert K.J., Mayer R.D., Wang Y., Sant G.R., Hanno P.M., Peters K.M., Kusek J.W. Responsiveness of symptom scales for interstitial cystitis. Urology. 2006;67:55–59. doi: 10.1016/j.urology.2005.07.014.
    1. Smith C.P., Radziszewski P., Borkowski A., Somogyi G.T., Boone T.B., Chancellor M.B. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871–875. doi: 10.1016/j.urology.2004.06.073. discussion 875.
    1. Meng J., Wang J., Lawrence G., Dolly J.O. Synaptobrevin i mediates exocytosis of cgrp from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J. Cell Sci. 2007;120:2864–2874. doi: 10.1242/jcs.012211.
    1. Lucioni A., Bales G.T., Lotan T.L., McGehee D.S., Cook S.P., Rapp D.E. Botulinum toxin type a inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–370. doi: 10.1111/j.1464-410X.2007.07312.x.
    1. Liu H.T., Kuo H.C. Intravesical botulinum toxin a injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70:463–468. doi: 10.1016/j.urology.2007.04.038.
    1. Liu H.T., Tyagi P., Chancellor M.B., Kuo H.C. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009;104:1476–1481. doi: 10.1111/j.1464-410X.2009.08675.x.
    1. Chapple C., Sievert K.D., MacDiarmid S., Khullar V., Radziszewski P., Nardo C., Thompson C., Zhou J., Haag-Molkenteller C. Onabotulinumtoxina 100 u significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur. Urol. 2013;64:249–256. doi: 10.1016/j.eururo.2013.04.001.
    1. Mangera A., Andersson K.E., Apostolidis A., Chapple C., Dasgupta P., Giannantoni A., Gravas S., Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin a: A systematic review of botox (onabotulinumtoxina) and dysport (abobotulinumtoxina) Eur. Urol. 2011;60:784–795. doi: 10.1016/j.eururo.2011.07.001.
    1. Yokoyama T., Chancellor M.B., Oguma K., Yamamoto Y., Suzuki T., Kumon H., Nagai A. Botulinum toxin type a for the treatment of lower urinary tract disorders. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2012;19:202–215. doi: 10.1111/j.1442-2042.2011.02946.x.
    1. Yoshida M., Miyamae K., Iwashita H., Otani M., Inadome A. Management of detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004;63:17–23. doi: 10.1016/j.urology.2003.11.003.
    1. Mukerji G., Yiangou Y., Grogono J., Underwood J., Agarwal S.K., Khullar V., Anand P. Localization of m2 and m3 muscarinic receptors in human bladder disorders and their clinical correlations. J. Urol. 2006;176:367–373. doi: 10.1016/S0022-5347(06)00563-5.
    1. Faubion S.S., Shuster L.T., Bharucha A.E. Recognition and management of nonrelaxing pelvic floor dysfunction. Mayo Clin. Proc. 2012;87:187–193. doi: 10.1016/j.mayocp.2011.09.004.
    1. Kuo Y.-C., Kuo H.-C. O’leary-Sant symptom index predicts the treatment outcome for onabotulinumtoxin a injections for refractory interstitial cystitis/bladder pain syndrome. Toxins. 2015;7:2860–2871. doi: 10.3390/toxins7082860.
    1. Karsenty G., Denys P., Amarenco G., De Seze M., Game X., Haab F., Kerdraon J., Perrouin-Verbe B., Ruffion A., Saussine C., et al. Botulinum toxin a (botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review. Eur. Urol. 2008;53:275–287. doi: 10.1016/j.eururo.2007.10.013.
    1. Chung S.D., Kuo Y.C., Kuo H.C. Intravesical onabotulinumtoxina injections for refractory painful bladder syndrome. Pain physician. 2012;15:197–202.
    1. Pinto R., Lopes T., Frias B., Silva A., Silva J.A., Silva C.M., Cruz C., Cruz F., Dinis P. Trigonal injection of botulinum toxin a in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 2010;58:360–365. doi: 10.1016/j.eururo.2010.02.031.
    1. Homma Y., Ueda T., Tomoe H., Lin A.T., Kuo H.C., Lee M.H., Lee J.G., Kim D.Y., Lee K.S. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2009;16:597–615. doi: 10.1111/j.1442-2042.2009.02326.x.
    1. Jiang Y.H., Ong H.L., Kuo H.C. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-a real-life practice of 290 cases in a single center. Neurourol. Urodyn. 2015 doi: 10.1002/nau.22892.
    1. Kuo H.C. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J. Urol. 2007;178:1359–1363. doi: 10.1016/j.juro.2007.05.136.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel